---
layout: post
title: "八大券商主题策略：中药板块行情具备可持续性！五大维度布局产业链标的"
date: 2022-04-06 12:23:42 +0800
categories: emnews
tags: 东财滚动新闻
---
> 国联证券表示，医药板块目前估值和仓位均处于历史底部区间，随着年报、一季报持续披露，高景气行业赛道有望率先反弹。

<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" data-code="BK1040|90|1" data-code2="BK1040|90|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1040&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1040_0" data-code="K BK1040|90|1" data-code2="K BK1040|90|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1060" data-code="BK1060|90|1" data-code2="BK1060|90|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1060&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1060_0" data-code="K BK1060|90|1" data-code2="K BK1060|90|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>每日主题策略讨论，<span id="stock_0.300059"><a href="http://quote.eastmoney.com/unify/r/0.300059" class="keytip" data-code="0,300059">东方财富</a></span><span id="quote_0.300059"></span>网汇总八大<span id="Info.3306"><a href="http://data.eastmoney.com/other/qsjy.html" class="infokey">券商</a></span>观点，揭秘行业现状，观察行情走势，提前为您把脉A股。<br /></p><center><img src="https://dfscdn.dfcfw.com/download/D25285964476450021218_w571h461.jpg" width="571" emheight="461" orginial_src="https://dfscdn.dfcfw.com/download/D25285964476450021218_w571h461_o.jpg" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p><strong><span id="stock_1.600030"><a href="http://quote.eastmoney.com/unify/r/1.600030" class="keytip" data-code="1,600030">中信证券</a></span><span id="quote_1.600030"></span>：<span id="bk_90.BK1040"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" class="keytip" data-code="90,BK1040">中药</a></span><span id="bkquote_90.BK1040"></span>板块行情具备可持续性 建议从五大维度去选择标的</strong></p><p><span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>板块在较长时间内处于谷底的迷茫期和困境期，2022年有望迎来困境反转；近年来国家大力支持<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>发展，不断出台相关政策，中药创新药的审批准则也在不断标准化，供给侧改革下迎来增量逻辑；在医药整体板块估值回调大背景下、中药板块作为低估值以及政策避风港等板块，有望迎来估值重塑；我们认为中药行情具有中长期可持续性，短期可关注结构性机会，中长期关注受益于政策推动、创新研发以及消费升级的标的企业。</p><p>受益于消费升级和政策扶持，整体中医药行业需求仍持续向好，中药板块行情具备可持续性。建议从五大维度去选择标的：①具备极强护城河、产品品牌壁垒高的龙头企业，例如<span id="stock_0.000538"><a href="http://quote.eastmoney.com/unify/r/0.000538" class="keytip" data-code="0,000538">云南白药</a></span><span id="quote_0.000538"></span>、<span id="stock_1.600436"><a href="http://quote.eastmoney.com/unify/r/1.600436" class="keytip" data-code="1,600436">片仔癀</a></span><span id="quote_1.600436"></span>等企业；②<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>增长的持续性与估值相匹配：建议关注受益于配方颗粒新国标改革后放量的<span id="stock_0.000999"><a href="http://quote.eastmoney.com/unify/r/0.000999" class="keytip" data-code="0,000999">华润三九</a></span><span id="quote_0.000999"></span>、<span id="Info.116.00570"><a href="http://quote.eastmoney.com/unify/r/116.00570" class="keytip" data-code="116,00570">中国中药</a></span>(H)、<span id="stock_0.300026"><a href="http://quote.eastmoney.com/unify/r/0.300026" class="keytip" data-code="0,300026">红日药业</a></span><span id="quote_0.300026"></span>；建议关注主营产品具备定价权、叠加涨价逻辑的<span id="stock_1.600285"><a href="http://quote.eastmoney.com/unify/r/1.600285" class="keytip" data-code="1,600285">羚锐制药</a></span><span id="quote_1.600285"></span>、<span id="stock_1.600129"><a href="http://quote.eastmoney.com/unify/r/1.600129" class="keytip" data-code="1,600129">太极集团</a></span><span id="quote_1.600129"></span>、<span id="stock_1.600422"><a href="http://quote.eastmoney.com/unify/r/1.600422" class="keytip" data-code="1,600422">昆药集团</a></span><span id="quote_1.600422"></span>；③管理层改善逻辑：建议关注<span id="stock_1.600085"><a href="http://quote.eastmoney.com/unify/r/1.600085" class="keytip" data-code="1,600085">同仁堂</a></span><span id="quote_1.600085"></span>、<span id="stock_1.600771"><a href="http://quote.eastmoney.com/unify/r/1.600771" class="keytip" data-code="1,600771">广誉远</a></span><span id="quote_1.600771"></span>等；④中药创新药增量逻辑：建议关注<span id="stock_0.002603"><a href="http://quote.eastmoney.com/unify/r/0.002603" class="keytip" data-code="0,002603">以岭药业</a></span><span id="quote_0.002603"></span>、<span id="stock_1.600557"><a href="http://quote.eastmoney.com/unify/r/1.600557" class="keytip" data-code="1,600557">康缘药业</a></span><span id="quote_1.600557"></span>；⑤中医服务提供商：建议关注<span id="Info.116.02273"><a href="http://quote.eastmoney.com/unify/r/116.02273" class="keytip" data-code="116,02273">固生堂</a></span>，新中医诊疗龙头，OMO 模式全国布局持续推进，建议关注<span id="stock_0.000705"><a href="http://quote.eastmoney.com/unify/r/0.000705" class="keytip" data-code="0,000705">浙江震元</a></span><span id="quote_0.000705"></span>。</p><p><strong><span id="stock_1.601456"><a href="http://quote.eastmoney.com/unify/r/1.601456" class="keytip" data-code="1,601456">国联证券</a></span><span id="quote_1.601456"></span>：医药板块目前估值和仓位均处于历史底部区间</strong></p><p>医药板块目前估值和仓位均处于历史底部区间，随着年报、一季报持续披露，高景气行业赛道有望率先反弹。</p><p>展望4月，建议关注业绩超预期个股，以及业绩增速较快、景气度高的细分领域：1)医疗新基建：2021年是中国医疗新基建启动元年，医疗设备行业增速有望提升。重点推荐<span id="stock_0.300760"><a href="http://quote.eastmoney.com/unify/r/0.300760" class="keytip" data-code="0,300760">迈瑞医疗</a></span><span id="quote_0.300760"></span>、<span id="stock_0.301235"><a href="http://quote.eastmoney.com/unify/r/0.301235" class="keytip" data-code="0,301235">华康医疗</a></span><span id="quote_0.301235"></span>等。</p><p>2)CXO:CXO 行业的订单需求旺盛，产能快速扩张，仍是医药行业中具备高业绩确定性和成长性的子行业。重点关注<span id="stock_1.603259"><a href="http://quote.eastmoney.com/unify/r/1.603259" class="keytip" data-code="1,603259">药明康德</a></span><span id="quote_1.603259"></span>、<span id="stock_1.688131"><a href="http://quote.eastmoney.com/unify/r/1.688131" class="keytip" data-code="1,688131">皓元医药</a></span><span id="quote_1.688131"></span>、<span id="stock_0.300725"><a href="http://quote.eastmoney.com/unify/r/0.300725" class="keytip" data-code="0,300725">药石科技</a></span><span id="quote_0.300725"></span>，建议关注<span id="stock_0.002821"><a href="http://quote.eastmoney.com/unify/r/0.002821" class="keytip" data-code="0,002821">凯莱英</a></span><span id="quote_0.002821"></span>、<span id="stock_0.300363"><a href="http://quote.eastmoney.com/unify/r/0.300363" class="keytip" data-code="0,300363">博腾股份</a></span><span id="quote_0.300363"></span>、<span id="stock_1.603456"><a href="http://quote.eastmoney.com/unify/r/1.603456" class="keytip" data-code="1,603456">九洲药业</a></span><span id="quote_1.603456"></span>、<span id="stock_1.688202"><a href="http://quote.eastmoney.com/unify/r/1.688202" class="keytip" data-code="1,688202">美迪西</a></span><span id="quote_1.688202"></span>等。</p><p>3)疫苗：HPV 疫苗是首个癌症预防型疫苗，有效性已得到多国验证，全球长期以来供不应求，随着国产疫苗上市、产能逐渐释放，有望迎来千亿市场。重点关注：<span id="stock_1.603392"><a href="http://quote.eastmoney.com/unify/r/1.603392" class="keytip" data-code="1,603392">万泰生物</a></span><span id="quote_1.603392"></span>、<span id="stock_0.300122"><a href="http://quote.eastmoney.com/unify/r/0.300122" class="keytip" data-code="0,300122">智飞生物</a></span><span id="quote_0.300122"></span>；建议关注：康乐卫士、瑞科生物、<span id="stock_0.300142"><a href="http://quote.eastmoney.com/unify/r/0.300142" class="keytip" data-code="0,300142">沃森生物</a></span><span id="quote_0.300142"></span>。</p><p>4)生命科学上游：行业受益于科研投入增加而高速增长，新冠疫情下国产品牌崭露头角，国产替代进程有望加速。重点关注<span id="stock_1.688105"><a href="http://quote.eastmoney.com/unify/r/1.688105" class="keytip" data-code="1,688105">诺唯赞</a></span><span id="quote_1.688105"></span>，建议关注<span id="stock_0.301080"><a href="http://quote.eastmoney.com/unify/r/0.301080" class="keytip" data-code="0,301080">百普赛斯</a></span><span id="quote_0.301080"></span>、<span id="stock_0.301047"><a href="http://quote.eastmoney.com/unify/r/0.301047" class="keytip" data-code="0,301047">义翘神州</a></span><span id="quote_0.301047"></span>、菲鹏生物。</p><p><strong><span id="stock_1.600369"><a href="http://quote.eastmoney.com/unify/r/1.600369" class="keytip" data-code="1,600369">西南证券</a></span><span id="quote_1.600369"></span>：业绩+政策+估值筑底 医药板块迎来最佳的布局时点</strong></p><p>业绩+政策+估值筑底，行业迎来布局良机。近期医药板块迎来了最佳的布局时点，结合2022年年度策略的两条主线：“穿越医保”和“疫情脱敏”，建议投资者重点关注几个板块性的布局机会：一方面，建议加配大市值龙头如<span web="1" href="http://quote.eastmoney.com/unify/r/0.300760" class="em_stock_key_common" data-code="0,300760">迈瑞医疗</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603259" class="em_stock_key_common" data-code="1,603259">药明康德</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300122" class="em_stock_key_common" data-code="0,300122">智飞生物</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600436" class="em_stock_key_common" data-code="1,600436">片仔癀</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.000538" class="em_stock_key_common" data-code="0,000538">云南白药</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600085" class="em_stock_key_common" data-code="1,600085">同仁堂</span>、<span id="stock_0.300896"><a href="http://quote.eastmoney.com/unify/r/0.300896" class="keytip" data-code="0,300896">爱美客</a></span><span id="quote_0.300896"></span>、<span id="stock_1.600276"><a href="http://quote.eastmoney.com/unify/r/1.600276" class="keytip" data-code="1,600276">恒瑞医药</a></span><span id="quote_1.600276"></span>等；</p><p>另一方面，持续推荐三个方向：1)中药板块：政策边际利好+提价+国企改革，推荐<span web="1" href="http://quote.eastmoney.com/unify/r/1.600129" class="em_stock_key_common" data-code="1,600129">太极集团</span>、<span id="stock_1.603896"><a href="http://quote.eastmoney.com/unify/r/1.603896" class="keytip" data-code="1,603896">寿仙谷</a></span><span id="quote_1.603896"></span>、<span id="stock_0.300181"><a href="http://quote.eastmoney.com/unify/r/0.300181" class="keytip" data-code="0,300181">佐力药业</a></span><span id="quote_0.300181"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.000999" class="em_stock_key_common" data-code="0,000999">华润三九</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002603" class="em_stock_key_common" data-code="0,002603">以岭药业</span>等；2)供应链自主可控：国际冲突进一步加强国内在供应链实现国产替代的意愿，推荐药机行业如<span id="stock_0.300358"><a href="http://quote.eastmoney.com/unify/r/0.300358" class="keytip" data-code="0,300358">楚天科技</a></span><span id="quote_0.300358"></span>、<span id="stock_0.300171"><a href="http://quote.eastmoney.com/unify/r/0.300171" class="keytip" data-code="0,300171">东富龙</a></span><span id="quote_0.300171"></span>等；3)低估值方向，建议关注PEG&lt;1弹性个股，如<span id="stock_1.605186"><a href="http://quote.eastmoney.com/unify/r/1.605186" class="keytip" data-code="1,605186">健麾信息</a></span><span id="quote_1.605186"></span>、<span id="stock_1.603108"><a href="http://quote.eastmoney.com/unify/r/1.603108" class="keytip" data-code="1,603108">润达医疗</a></span><span id="quote_1.603108"></span>、<span id="stock_0.300049"><a href="http://quote.eastmoney.com/unify/r/0.300049" class="keytip" data-code="0,300049">福瑞股份</a></span><span id="quote_0.300049"></span>等。最后，建议关注新冠药物/检测/疫苗产业链等主题性投资机会。</p><p><strong><span id="stock_0.002736"><a href="http://quote.eastmoney.com/unify/r/0.002736" class="keytip" data-code="0,002736">国信证券</a></span><span id="quote_0.002736"></span>：中医药“十四五规划”出炉 传承与发扬中医药成为主调</strong></p><p>中医药“十四五规划”出炉，传承与发扬中医药成为主调。3 月29 日，国务院办公厅印发《“十四五”中医药发展规划》，这是首个以国务院办公厅名义印发的中医药五年规划，指标的设定更加体现新时期中医药高质量发展要求。在“十四五”中医药发展规划的设定目标中，多项人均指标大幅提升。规划还明确了十大主要任务，涉及中医诊疗的方方面面，彰显中医药在健康服务中的特色优势，体现在疾病预防(如新冠治疗指南中所涉及的中医预防方)、优势专科(比如心脑血管、皮肤、康复等)等方面。</p><p>政策景气周期已至，看好三类中药标的：1)扩容细分赛道：看好拥有上游种植(养殖)资源、标准高、布局早的中药配方颗粒生产企业。推荐买入：<span web="1" href="http://quote.eastmoney.com/unify/r/116.00570" class="em_stock_key_common" data-code="116,00570">中国中药</span>；2)回归药品属性，产品疗效确切、具备持续出新能力的优质企业：看好产品经循证医学充分验证、得到医生群体认可的优秀中药企业。推荐买入：<span web="1" href="http://quote.eastmoney.com/unify/r/0.002603" class="em_stock_key_common" data-code="0,002603">以岭药业</span>；3)消费属性标的：看好产品占领消费者心智、格局稳定、长期积累下拥有良好品牌形象的OTC 龙头企业。推荐买入：<span web="1" href="http://quote.eastmoney.com/unify/r/0.000999" class="em_stock_key_common" data-code="0,000999">华润三九</span>。</p><p><strong><span id="stock_1.601878"><a href="http://quote.eastmoney.com/unify/r/1.601878" class="keytip" data-code="1,601878">浙商证券</a></span><span id="quote_1.601878"></span>：迈入4月年报密集披露期 短期业绩增速可能催化医药行情</strong></p><p>迈入4 月年报密集披露期后，短期业绩增速可能构成催化，我们持续看好2022Q1 维持较高速增长、中长期产业升级逻辑清晰的医药制造板块，如CXO、原料药、制药上游等公司。</p><p>我们建议投资者打破“核心资产”和“板块观念”，才能够产业链思维看待上游、制造环节的投资机会，创新药械在过渡期内持续优胜劣汰，我们认为2022年医药应当坚持“握制造、迎创新”的投资策略。</p><p>具体而言，建议关注：1)制造板块：API、CDMO 等细分领域，推荐<span id="stock_1.603707"><a href="http://quote.eastmoney.com/unify/r/1.603707" class="keytip" data-code="1,603707">健友股份</a></span><span id="quote_1.603707"></span>、<span id="stock_0.000739"><a href="http://quote.eastmoney.com/unify/r/0.000739" class="keytip" data-code="0,000739">普洛药业</a></span><span id="quote_0.000739"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603259" class="em_stock_key_common" data-code="1,603259">药明康德</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002821" class="em_stock_key_common" data-code="0,002821">凯莱英</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603456" class="em_stock_key_common" data-code="1,603456">九洲药业</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300363" class="em_stock_key_common" data-code="0,300363">博腾股份</span>、<span id="stock_0.300630"><a href="http://quote.eastmoney.com/unify/r/0.300630" class="keytip" data-code="0,300630">普利制药</a></span><span id="quote_0.300630"></span>等。</p><p>2)上游：制药装备、试剂、耗材等领域，推荐<span id="Info.116.02155"><a href="http://quote.eastmoney.com/unify/r/116.02155" class="keytip" data-code="116,02155">森松国际</a></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300171" class="em_stock_key_common" data-code="0,300171">东富龙</span>、<span id="stock_1.688133"><a href="http://quote.eastmoney.com/unify/r/1.688133" class="keytip" data-code="1,688133">泰坦科技</a></span><span id="quote_1.688133"></span>、<span id="stock_1.688179"><a href="http://quote.eastmoney.com/unify/r/1.688179" class="keytip" data-code="1,688179">阿拉丁</a></span><span id="quote_1.688179"></span>、<span id="stock_1.688356"><a href="http://quote.eastmoney.com/unify/r/1.688356" class="keytip" data-code="1,688356">键凯科技</a></span><span id="quote_1.688356"></span>等，关注<span id="stock_1.688139"><a href="http://quote.eastmoney.com/unify/r/1.688139" class="keytip" data-code="1,688139">海尔生物</a></span><span id="quote_1.688139"></span>、<span id="stock_0.300813"><a href="http://quote.eastmoney.com/unify/r/0.300813" class="keytip" data-code="0,300813">泰林生物</a></span><span id="quote_0.300813"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300358" class="em_stock_key_common" data-code="0,300358">楚天科技</span>、<span id="stock_1.688301"><a href="http://quote.eastmoney.com/unify/r/1.688301" class="keytip" data-code="1,688301">奕瑞科技</a></span><span id="quote_1.688301"></span>、<span id="stock_1.688677"><a href="http://quote.eastmoney.com/unify/r/1.688677" class="keytip" data-code="1,688677">海泰新光</a></span><span id="quote_1.688677"></span>等。</p><p>3)创新：国际化能力的器械、药品公司，建议关注<span id="stock_1.688029"><a href="http://quote.eastmoney.com/unify/r/1.688029" class="keytip" data-code="1,688029">南微医学</a></span><span id="quote_1.688029"></span>、<span id="Info.116.00853"><a href="http://quote.eastmoney.com/unify/r/116.00853" class="keytip" data-code="116,00853">微创医疗</a></span>、<span id="stock_1.688198"><a href="http://quote.eastmoney.com/unify/r/1.688198" class="keytip" data-code="1,688198">佰仁医疗</a></span><span id="quote_1.688198"></span>、<span id="Info.116.06160"><a href="http://quote.eastmoney.com/unify/r/116.06160" class="keytip" data-code="116,06160">百济神州</a></span>、<span id="Info.116.01801"><a href="http://quote.eastmoney.com/unify/r/116.01801" class="keytip" data-code="116,01801">信达生物</a></span>、<span id="Info.116.01877"><a href="http://quote.eastmoney.com/unify/r/116.01877" class="keytip" data-code="116,01877">君实生物</a></span>、康方生物等。</p><p>4)其他：消费属性、<span id="bk_90.BK0727"><a href="http://quote.eastmoney.com/unify/r/90.BK0727" class="keytip" data-code="90,BK0727">医疗服务</a></span><span id="bkquote_90.BK0727"></span>、创新配套产业公司，推荐<span id="stock_0.300347"><a href="http://quote.eastmoney.com/unify/r/0.300347" class="keytip" data-code="0,300347">泰格医药</a></span><span id="quote_0.300347"></span>、<span id="stock_1.603127"><a href="http://quote.eastmoney.com/unify/r/1.603127" class="keytip" data-code="1,603127">昭衍新药</a></span><span id="quote_1.603127"></span>，关注<span web="1" href="http://quote.eastmoney.com/unify/r/0.300122" class="em_stock_key_common" data-code="0,300122">智飞生物</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603392" class="em_stock_key_common" data-code="1,603392">万泰生物</span>、<span id="stock_1.688185"><a href="http://quote.eastmoney.com/unify/r/1.688185" class="keytip" data-code="1,688185">康希诺</a></span><span id="quote_1.688185"></span>、<span id="stock_0.300601"><a href="http://quote.eastmoney.com/unify/r/0.300601" class="keytip" data-code="0,300601">康泰生物</a></span><span id="quote_0.300601"></span>、<span id="stock_0.300015"><a href="http://quote.eastmoney.com/unify/r/0.300015" class="keytip" data-code="0,300015">爱尔眼科</a></span><span id="quote_0.300015"></span>、<span id="stock_1.600763"><a href="http://quote.eastmoney.com/unify/r/1.600763" class="keytip" data-code="1,600763">通策医疗</a></span><span id="quote_1.600763"></span>、<span id="stock_1.600566"><a href="http://quote.eastmoney.com/unify/r/1.600566" class="keytip" data-code="1,600566">济川药业</a></span><span id="quote_1.600566"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600436" class="em_stock_key_common" data-code="1,600436">片仔癀</span>等。</p><p><strong>东莞<span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>：财报披露高峰期即将到来 关注绩优医药股的表现机会</strong></p><p>2021年报及2022年一季报披露高峰期即将到来，关注财报业绩有望超预期个股的表现机会。建议关注景气度保持向好、业绩有望超预期的CXO公司<span id="Info.116.02359"><a href="http://quote.eastmoney.com/unify/r/116.02359" class="keytip" data-code="116,02359">药明康德</a></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300347" class="em_stock_key_common" data-code="0,300347">泰格医药</span>、<span id="stock_0.300759"><a href="http://quote.eastmoney.com/unify/r/0.300759" class="keytip" data-code="0,300759">康龙化成</a></span><span id="quote_0.300759"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603127" class="em_stock_key_common" data-code="1,603127">昭衍新药</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002821" class="em_stock_key_common" data-code="0,002821">凯莱英</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300363" class="em_stock_key_common" data-code="0,300363">博腾股份</span>、九州药业、<span web="1" href="http://quote.eastmoney.com/unify/r/1.688202" class="em_stock_key_common" data-code="1,688202">美迪西</span>等；有望受益需求上升的新冠抗原检测试剂相关企业<span id="stock_0.300482"><a href="http://quote.eastmoney.com/unify/r/0.300482" class="keytip" data-code="0,300482">万孚生物</a></span><span id="quote_0.300482"></span>、<span id="stock_1.688298"><a href="http://quote.eastmoney.com/unify/r/1.688298" class="keytip" data-code="1,688298">东方生物</a></span><span id="quote_1.688298"></span>、<span id="stock_1.688075"><a href="http://quote.eastmoney.com/unify/r/1.688075" class="keytip" data-code="1,688075">安旭生物</a></span><span id="quote_1.688075"></span>、<span id="stock_1.688068"><a href="http://quote.eastmoney.com/unify/r/1.688068" class="keytip" data-code="1,688068">热景生物</a></span><span id="quote_1.688068"></span>、<span id="stock_1.688575"><a href="http://quote.eastmoney.com/unify/r/1.688575" class="keytip" data-code="1,688575">亚辉龙</a></span><span id="quote_1.688575"></span>、<span id="stock_0.002932"><a href="http://quote.eastmoney.com/unify/r/0.002932" class="keytip" data-code="0,002932">明德生物</a></span><span id="quote_0.002932"></span>等；关注研发能力强、非新冠产品有望实现快增的疫苗企业智飞生物、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300601" class="em_stock_key_common" data-code="0,300601">康泰生物</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300142" class="em_stock_key_common" data-code="0,300142">沃森生物</span>等。估值相对合理的<span id="bk_90.BK1041"><a href="http://quote.eastmoney.com/unify/r/90.BK1041" class="keytip" data-code="90,BK1041">医疗器械</a></span><span id="bkquote_90.BK1041"></span>龙头<span web="1" href="http://quote.eastmoney.com/unify/r/0.300760" class="em_stock_key_common" data-code="0,300760">迈瑞医疗</span>、医美龙头<span web="1" href="http://quote.eastmoney.com/unify/r/0.300896" class="em_stock_key_common" data-code="0,300896">爱美客</span>、OK镜龙头<span id="stock_0.300595"><a href="http://quote.eastmoney.com/unify/r/0.300595" class="keytip" data-code="0,300595">欧普康视</a></span><span id="quote_0.300595"></span>、眼科器械龙头<span id="stock_1.688050"><a href="http://quote.eastmoney.com/unify/r/1.688050" class="keytip" data-code="1,688050">爱博医疗</a></span><span id="quote_1.688050"></span>等；中期有望受益老龄化、内生增长动力较强的连锁医疗龙头<span web="1" href="http://quote.eastmoney.com/unify/r/0.300015" class="em_stock_key_common" data-code="0,300015">爱尔眼科</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600763" class="em_stock_key_common" data-code="1,600763">通策医疗</span>；估值有所回落、业绩有望向好的品牌中药片仔癀、<span web="1" href="http://quote.eastmoney.com/unify/r/0.000538" class="em_stock_key_common" data-code="0,000538">云南白药</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600085" class="em_stock_key_common" data-code="1,600085">同仁堂</span>等。</p><p><strong><span id="stock_1.600918"><a href="http://quote.eastmoney.com/unify/r/1.600918" class="keytip" data-code="1,600918">中泰证券</a></span><span id="quote_1.600918"></span>：国内散发疫情紧张 建议把握抗原检测产业链投资窗口</strong></p><p>3 月板块行情主要围绕年报一季报、新冠相关产业链、中药展开。医药板块自2021年7月至今，经历了连续三个季度的调整，当前估值28.6倍PE(历史平均37.2倍)，进入非常舒适的配置区间。我们认为全年医药板块行情将继续围绕业绩、新冠、低估值三条主线，继续看好医药板块行情的延续；同时，随着4 月进入一季报窗口期，业绩的权重有望进一步增加，建议结合季报积极把握。</p><p>1)季报业绩表现亮眼：4月窗口期，我们重点看好一季报业绩有望快速增长的板块和个股：①CDMO/CRO:市场悲观预期逐步释放，板块基本面持续强劲，景气有望延续，估值历史低位；②疫苗：疫情持续反复，加强针有序推进，估值调整到位；③API:困境反转叠加新冠口服药进展催化，API 景气后周期开启，有望成为全年医药核心主线，具备持续投资机会；④检测产业链：国内散发疫情紧张，建议把握抗原检测产业链投资窗口。</p><p>2)新冠产业链：各地出现持续散发疫情，新冠产业链不断有进展催化：多款新冠抗原自测试剂盒获批，<span id="stock_106.PFE"><a href="http://quote.eastmoney.com/unify/r/106.PFE" class="keytip" data-code="106,PFE">辉瑞</a></span><span id="quote_106.PFE"></span>Paxlovid 被写入最新版新冠诊疗方案，<span web="1" href="http://quote.eastmoney.com/unify/r/106.PFE" class="em_stock_key_common" data-code="106,PFE">辉瑞</span>Paxlovid MPP授权出炉，<span web="1" href="http://quote.eastmoney.com/unify/r/116.01877" class="em_stock_key_common" data-code="116,01877">君实生物</span>VV116 临床进展顺利推进，真实生物相继申请Ⅱ类、Ⅲ类会议的沟通交流，盐野义S-217622 Ⅲ期临床试验启动。从疫情反复、口服药研发进展、项目订单催化落实到最后对业绩的贡献上，我们看好基本面支撑叠加新冠业务弹性的口服药产业链及检测，前者看好海外新冠药物原研CDMO、国内研发及生产代工企业、海外仿制药MPP 授权等，后者建议关注头部IVD 检测标的，以及相关试剂、耗材上游标的等。</p><p>3)中药：3月29日，国务院办公厅印发《“十四五”中医药发展规划》，明确了“十四五”期间中医药发展的指导思想、基本原则、发展目标、主要任务和重点措施。我们认为，本次规划从产业、服务、支付等多个方面做出了政策顶层设计及战略规划，明确了中医药的未来发展路径，我国中医药产业在不断的政策利好推动下，有望迎来新一轮发展机遇，建议关注产业链相关受益标的，如片仔癀、云南白药、同仁堂、以岭药业、华润三九、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600566" class="em_stock_key_common" data-code="1,600566">济川药业</span>、<span id="stock_1.600329"><a href="http://quote.eastmoney.com/unify/r/1.600329" class="keytip" data-code="1,600329">中新药业</a></span><span id="quote_1.600329"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600129" class="em_stock_key_common" data-code="1,600129">太极集团</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600285" class="em_stock_key_common" data-code="1,600285">羚锐制药</span>等。</p><p><strong>万联<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>：中医药行业持续迎来政策利好 建议关注相关赛道投资机会</strong></p><p>顶层设计支持，中医药行业持续迎来政策利好，建议关注相关赛道投资机会。1)中药OTC:政策免疫性强，控费降价风险小，企业布局院外市场动力足，行业未来扩容可期；2)中药创新：结合现代的先进研究手段进行创新，在优势领域布局研发管线是中药企业核心竞争力之一，政策加大对中医药科技创新支持力度，企业有望在传承的基础上，加快创新转型；3)中药配方颗粒：需求扩增(终端放开)+医保准入落地，带动产业扩容；4)新冠治疗相关中医药赛道：国家认可中医药在包括新冠肺炎等重大传染病防控工作中的作用，并将部分中药和<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0727" class="em_stock_key_common" data-code="90,BK0727">医疗服务</span>纳入新冠肺炎诊疗方案中，中医药战略地位进一步提高；5)中医医疗：国家支持扩大优质中医医疗资源总量，鼓励社会力量在基层办中医，带动中医医疗产业扩容；6)中医药出海：借“疫”出海，推动中医药企业开拓国际重点市场，中医药海外注册销售迎来契机。</p><p class="em_media">（文章来源：<span web="1" href="http://quote.eastmoney.com/unify/r/0.300059" class="em_stock_key_common" data-code="0,300059">东方财富</span>研究中心）</p>

<http://stock.eastmoney.com/news/1405,202204062333356834.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)